We found that systemic injection of miR-329 mimic incorporated into albumin-sericin nanocarriers at therapeutic doses resulted in significant in vivo tumor integration of miR-329 and inhibition of the desired target genes in multiple triple-negative breast cancer (TNBC) models. Here, ALB is linked to neoplasm.